Concerted Action of PGC-1-related Coactivator (PRC) and C-MYC in the Stress Response to Mitochondrial Dysfunction
Overview
Authors
Affiliations
PGC-1-related coactivator (PRC) has a dual function in growth-regulated mitochondrial biogenesis and as a sensor of metabolic stress. PRC induction by mitochondrial inhibitors, intracellular ROS, or topoisomerase I inhibition orchestrates an inflammatory program associated with the adaptation to cellular stress. Activation of this program is accompanied by the coordinate expression of c-MYC, which is linked kinetically to that of PRC in response to multiple stress inducers. Here, we show that the c-MYC inhibitor 10058-F4 blocks the induction of c-MYC, PRC, and representative PRC-dependent stress genes by the respiratory chain uncoupler, carbonyl cyanide m-chlorophenyl hydrazine (CCCP). This result, confirmed by the suppression of PRC induction by c-MYC siRNA silencing, demonstrates a requirement for c-MYC in orchestrating the stress program. PRC steady-state expression was markedly increased upon mutation of two GSK-3 serine phosphorylation sites within the carboxyl-terminal domain. The negative control of PRC expression by GSK-3 was consistent with the phosphor-inactivation of GSK-3β by CCCP and by the induction of PRC by the GSK-3 inhibitor AZD2858. Unlike PRC, which was induced post-translationally through increased protein half-life, c-MYC was induced predominantly at the mRNA level. Moreover, suppression of Akt activation by the Akt inhibitor MK-2206 blocked the CCCP induction of PRC, c-MYC, and representative PRC stress genes, demonstrating a requirement for Akt signaling. MK-2206 also inhibited the phosphor-inactivation of GSK-3β by CCCP, a result consistent with the ability of Akt to phosphorylate, and thereby suppress GSK-3 activity. Thus, PRC and c-MYC can act in concert through Akt-GSK-3 signaling to reprogram gene expression in response to mitochondrial stress.
Eugenol Promotes Apoptosis in Leukemia Cells via Targeting the Mitochondrial Biogenesis PPRC1 Gene.
Al-Harbi S, Alkholiwy E, Ali Ahmed S, Aljurf M, Al-Hejailan R, Aboussekhra A Cells. 2025; 14(4).
PMID: 39996733 PMC: 11853370. DOI: 10.3390/cells14040260.
Pan X, Hao E, Zhang F, Wei W, Du Z, Yan G Front Pharmacol. 2024; 15:1401961.
PMID: 39045049 PMC: 11263127. DOI: 10.3389/fphar.2024.1401961.
MYC-an emerging player in mitochondrial diseases.
Purhonen J, Klefstrom J, Kallijarvi J Front Cell Dev Biol. 2023; 11:1257651.
PMID: 37731815 PMC: 10507175. DOI: 10.3389/fcell.2023.1257651.
Purhonen J, Banerjee R, Wanne V, Sipari N, Morgelin M, Fellman V Nat Commun. 2023; 14(1):2356.
PMID: 37095097 PMC: 10126100. DOI: 10.1038/s41467-023-38027-1.
Gravel S, Ben Khalifa Y, McGuirk S, St-Louis C, Laurin K, Lavallee E iScience. 2023; 26(4):106314.
PMID: 37009228 PMC: 10064239. DOI: 10.1016/j.isci.2023.106314.